Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Posted on 17 Nov 2026
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further complicates care, highlighting the need for rapid coagulation assessment to guide timely intervention. A newly cleared cartridge expands point-of-care viscoelastic testing to trauma care, enabling assessment of perioperative hemorrhage and/or thrombosis.
Werfen has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ROTEM sigma complete cartridge to assess peri-operative hemorrhage and/or thrombosis in trauma patients. The clearance expands the use of the ROTEM sigma viscoelastic testing system in the United States beyond cardiovascular surgery and liver transplantation to include trauma care. The system is indicated for adults aged 21 years and older when a semiquantitative evaluation of blood coagulation properties is needed in point-of-care or laboratory settings.

ROTEM sigma is a fully automated in vitro diagnostic viscoelastic testing system designed to monitor and assess coagulation status by measuring the viscoelastic properties of 3.2% citrated venous or arterial whole blood samples. It provides real-time information on clot initiation, clot firmness, and clot stability, helping clinicians evaluate coagulation abnormalities and guide treatment decisions. Results are intended to be interpreted alongside the patient’s clinical condition and other laboratory findings. The system is designed for use in point-of-care and laboratory settings but is not intended for pre-hospital trauma care.
The cartridge-based platform uses closed-tube direct sampling to minimize manual handling and reduce operator-dependent variability. The ROTEM sigma complete cartridge incorporates four assays, INTEM C, EXTEM C, FIBTEM C, and APTEM C, in a single-use, multichannel format to evaluate coagulation through different pathways, including assessments that isolate clot firmness from platelet contributions or inhibit fibrinolysis.
To streamline testing and support workflow efficiency, the system also features automated assay initiation, integrated quality control, continuous internal monitoring, touchscreen operation, and room-temperature cartridge storage. Additional capabilities include large TEMograms for visualizing coagulation dynamics and live result viewing through GEMweb Live.
“Trauma teams are required to make critical treatment decisions within minutes, when every moment matters. The clearance of the ROTEM sigma complete cartridge for use in trauma expands access to rapid, actionable coagulation information at the point of care, helping make informed treatment decisions during trauma resuscitation. This milestone underscores our commitment to bleeding management and providing clinicians with innovative tools that support timely, evidence-based care,” said Bill Crandell, Vice President, Commercial Operations, North America at Werfen.







